瑞巴派特对各种原因引起的胃溃疡愈合状况的疗效观察

Effect of Rebamipide(mucosta) on Non-steroidal Anti-inflammatory Drugs-related Gastric Ulcer Healing

目的探讨瑞巴派特(膜固思达)对各种原因引起的胃溃疡愈合状况的影响。方法胃窦及胃体取活检证实为胃溃疡的60例患者,根据幽门螺杆菌(Helicobacter pylori,HP)感染状况和非甾体抗炎药(nonsteroidal anti-inflammatory drags,NSAIDs)相关性分组,其中HP感染状况依据快速尿素酶试验、组织病理学检查以及尿素呼气试验判定,NSAIDs相关性依据NSAIDs使用史判定。所有患者均给予瑞巴派特100mg每日3次口服,持续8周。在第4周和第8周进行不良反应随访,最后复查胃镜评价溃疡愈合程度。结果有NSAIDs使用史的患者大部分完全愈合(70%),所有患者对治疗结果满意且无明显不良反应。结论瑞巴派特对NSAIDs相关性溃疡疗效显著,可以明显促进溃疡愈合改善临床症状。

Objective To investigate the effect of rebamipide（mucosta）on gastric ulcer healing caused by various etiologies. Methods Sixty cases of gastric ulcer were grouped based on the helicobacter pylori （HP） infection and the relation to use of （NSAIDs）. The helicobacter pylori （HP） infection was determined by using rapid urease test,histopathological examination and the urea breath test,and the relation to NSAIDs was evaluated by the NSAIDs-taking history. All patients received rebamipide 100 mg,three times a day,for 8 weeks. The adverse effects were assessed at Weeks 4 and 8 after administration. At the end of the present study,the endoscopic evaluation of ulcer healing was carried out. Results Ulcers were completely healed（70%） in most patients with NSAIDs-related ulcer. All patients were satisfied with the therapy results due to few adverse effects. Conclusion Rebamipide has a significant effect on NSAIDs-related ulcer and can clearly improve the clinical symptoms to promote ulcer healing.